Biltmore Capital Advisors LLC Buys New Position in Catalyst Pharmaceuticals Inc (CPRX)

Share on StockTwits

Biltmore Capital Advisors LLC bought a new stake in shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 15,400 shares of the biopharmaceutical company’s stock, valued at approximately $79,000.

Other large investors have also added to or reduced their stakes in the company. Amalgamated Bank purchased a new position in Catalyst Pharmaceuticals during the 4th quarter valued at about $28,000. Paloma Partners Management Co purchased a new position in Catalyst Pharmaceuticals during the 4th quarter valued at about $30,000. Metropolitan Life Insurance Co. NY grew its stake in Catalyst Pharmaceuticals by 291.8% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 27,253 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 20,297 shares in the last quarter. Meeder Asset Management Inc. grew its stake in Catalyst Pharmaceuticals by 185.1% during the 4th quarter. Meeder Asset Management Inc. now owns 34,237 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 22,227 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in Catalyst Pharmaceuticals by 18.3% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 36,700 shares of the biopharmaceutical company’s stock valued at $70,000 after acquiring an additional 5,688 shares in the last quarter. 59.79% of the stock is currently owned by institutional investors.

Several equities analysts have weighed in on the company. Zacks Investment Research raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a research note on Tuesday, May 21st. HC Wainwright set a $9.00 price target on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, May 14th. BidaskClub cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 9th. ValuEngine cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 8th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $10.00 price target on shares of Catalyst Pharmaceuticals in a research note on Tuesday, May 7th. Seven investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average target price of $7.35.

Shares of NASDAQ CPRX opened at $3.61 on Monday. The company has a market capitalization of $371.30 million, a P/E ratio of -10.94 and a beta of 2.43. Catalyst Pharmaceuticals Inc has a 52 week low of $1.85 and a 52 week high of $6.16. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.08 and a quick ratio of 6.07.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings results on Monday, May 13th. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.12. The firm had revenue of $12.45 million during the quarter, compared to the consensus estimate of $2.40 million. During the same period in the previous year, the firm posted ($0.06) EPS. As a group, equities analysts forecast that Catalyst Pharmaceuticals Inc will post 0.11 earnings per share for the current year.

WARNING: This article was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/4353949/biltmore-capital-advisors-llc-buys-new-position-in-catalyst-pharmaceuticals-inc-cprx.html.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.

Featured Article: What is a Fibonacci Channel?

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals Inc (NASDAQ:CPRX).

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

TowneBank  Downgraded by ValuEngine
TowneBank Downgraded by ValuEngine
Tonix Pharmaceuticals  Stock Rating Lowered by ValuEngine
Tonix Pharmaceuticals Stock Rating Lowered by ValuEngine
1st Source  Rating Lowered to Sell at ValuEngine
1st Source Rating Lowered to Sell at ValuEngine
ValuEngine Downgrades Sunesis Pharmaceuticals  to Sell
ValuEngine Downgrades Sunesis Pharmaceuticals to Sell
ValuEngine Downgrades QEP Resources  to Strong Sell
ValuEngine Downgrades QEP Resources to Strong Sell
ValuEngine Downgrades SemGroup  to Hold
ValuEngine Downgrades SemGroup to Hold


© 2006-2019 Ticker Report